MediWound (MDWD) Misses Q4 EPS by 63c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. WDAY
2. NVDA
3. META
4. JNJ
5. AAPL
6. AMAT
7. SPY
8. ASML
9. NRIX
10. SUNS

Go back to MediWound (MDWD) Misses Q4 EPS by 63c

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

March 16, 2023 7:10 AM EDT

2022 total revenues of $26.5 million

FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second quarter of 2023

EscharEx® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023

Cash position of $66 million, including cash received for the NexoBrid approval milestone and recent equity financing

Conference call begins today at... More